In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:ROS1-gene fusions in advanced lung cancerROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHCComparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitorsAdvantages of RNA- vs DNA-based next-generation sequencing Program faculty:Jessica J. Lin, MDAttending PhysicianMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsAlice T. Shaw, MD, PhDChief, Strategic PartnershipsAttending Physician, Thoracic OncologyDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsResources:To download the slides associated with this podcast discussion, please visit the program page